Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

iCAD, Inc. ICAD NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
43/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

iCAD, Inc. (ICAD) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 8 Buy, 2 Hold.

ICAD Analyst Ratings

Buy
10
Ratings
8 Buy
2 Hold
Based on 10 analysts giving stock ratings to iCAD, Inc. in the past 3 months
Rating breakdown
Buy
8 80%
Hold
2 20%
80%
Buy
8 analysts
20%
Hold
2 analysts
0%
Sell
0 analysts

People Also View

ESTA
ESTA
Establishment Labs Holdings Inc.
$66.61
+0.20%
 AXGN
AXGN
AxoGen, Inc.
$34.76
+0.87%
 FNA
FNA
Paragon 28, Inc.
$13.09
+0.00%
 SIBN
SIBN
SI-BONE, Inc.
$14.49
+0.42%
 SRDX
SRDX
Surmodics, Inc.
$42.98
+0.35%
 NVRO
NVRO
Nevro Corp.
$5.84
+0.00%
 SGHT
SGHT
Sight Sciences, Inc.
$3.91
+2.36%
 CVRX
CVRX
CVRx, Inc.
$7.48
-3.11%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message